Researchers find protein that might be key to cutting cancer cells' blood supply

May 12, 2011

UT Southwestern Medical Center researchers have discovered a protein that guides blood vessel development and eventually might lead to a treatment to keep cancer cells from spreading.

The researchers showed in mice that the Ras interacting protein 1 (Rasip1) is so specific and central to so many cellular processes that without it new simply cannot form, said Dr. Ondine Cleaver, assistant professor of molecular biology at UT Southwestern and senior author of the study in the April issue of Developmental Cell.

"What we've found is really the first factor that is important in all blood vessels for inner channel formation and tubulogenesis, i.e., the transformation of something that looks like a rope into something that looks like a garden hose," Dr. Cleaver said.

depend on the body's creation of new blood vessels to deliver the nutrients that fuel cancer's rapid growth. Cancerous tumors also use the circulatory system as a superhighway through which they send malignant cells to colonize other parts of the body. A Rasip1-blocking drug conceivably could fight cancer on two fronts: by starving the cancerous cells and by cutting off their transport routes, Dr. Cleaver said.

During fetal development the body creates many tube-shaped organs such as the intestines of the digestive system and the vessels of the cardiovascular system. The mechanisms by which blood vessel progenitor cells transform into tubes that can carry blood are only beginning to be understood, she said.

Scientists have found many regulatory molecules important in different tissues and even in other aspects of blood vessel formation or maintenance, but all of them are active in multiple body tissues. Rasip1 is the first blood vessel-specific regulator of molecular switches called GTPases, she said. The protein appears to be active only in the endothelium, the layer of cells that line the blood vessels, and is not found in the smooth muscle cells that make up the outside of the vessels.

The UT Southwestern scientists also discovered that Rasip1 and a protein binding partner are both required for blood vessels to form channels through which blood can flow, she said.

Most approaches to therapies aimed at blocking blood vessel formation have focused on growth factors that occur outside the cell rather than intrinsic cellular growth factors like Rasip1, Dr. Cleaver said.

"Although this is still a mouse study, we feel that future studies of Rasip1 and the molecular processes under its control hold great promise to provide tools and models for advancing clinical therapies aimed at blocking in tumors," she said.

The researchers now plan to look for drugs that block Rasip1 in order to eventually develop strategies to stop the growth of functional blood vessels and starve cancerous tumors, she said.

Related Stories

Recommended for you

Stem cell therapy attacks cancer by targeting unique tissue stiffness

July 26, 2017
A stem cell-based method created by University of California, Irvine scientists can selectively target and kill cancerous tissue while preventing some of the toxic side effects of chemotherapy by treating the disease in a ...

Understanding cell segregation mechanisms that help prevent cancer spread

July 26, 2017
Scientists have uncovered how cells are kept in the right place as the body develops, which may shed light on what causes invasive cancer cells to migrate.

Study uncovers potential 'silver bullet' for preventing and treating colon cancer

July 26, 2017
In preclinical experiments, researchers at VCU Massey Cancer Center have uncovered a new way in which colon cancer develops, as well as a potential "silver bullet" for preventing and treating it. The findings may extend to ...

Compound shows promise in treating melanoma

July 26, 2017
While past attempts to treat melanoma failed to meet expectations, an international team of researchers are hopeful that a compound they tested on both mice and on human cells in a petri dish takes a positive step toward ...

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.